Administration of anti-HER2 antibody after nonmyeloablative allogeneic stem cell transplantation in metastatic breast cancer

por Banna, G L, Aversa, S M L, Crivellari, G, Ghiotto, C, Chiarion-Sileni, V, Monfardini, S
Publicado 2006

Report from the Melanoma Independent Board First Melanoma MIB Conference, 21–22 October 2013

por Testori, A, Ascierto, P, Chiarion Sileni, V, De Lorenzo, F, Pelicci, PG, Rossi, CR
Publicado 2014

Surgery and radiotherapy in the treatment of cutaneous melanoma

por Testori, A., Rutkowski, P., Marsden, J., Bastholt, L., Chiarion-Sileni, V., Hauschild, A., Eggermont, A. M. M.
Publicado 2009

Optimization of resources by drug management: A multicentred web-administered study on the use of ipilimumab in Italy

por Damuzzo, V, Russi, A, Chiumente, M, Masini, C, Rebesco, B, Gregis, F, Nozza, S, Pigozzo, J, Chiarion-Sileni, V, Palozzo, AC
Publicado 2018

Phase II trial of docetaxel, cisplatin and fluorouracil followed by carboplatin and radiotherapy in locally advanced oesophageal cancer

por Chiarion-Sileni, V, Corti, L, Ruol, A, Innocente, R, Boso, C, Del Bianco, P, Pigozzo, J, Mazzarotto, R, Tomassi, O, Ancona, E
Publicado 2007

Central nervous system failure in melanoma patients: results of a randomised, multicentre phase 3 study of temozolomide- and dacarbazine- based regimens

por Chiarion-Sileni, V, Guida, M, Ridolfi, L, Romanini, A, Del Bianco, P, Pigozzo, J, Brugnara, S, Colucci, G, Ridolfi, R, De Salvo, G L
Publicado 2011

Small molecules and targeted therapies in distant metastatic disease

por Hersey, P., Bastholt, L., Chiarion-Sileni, V., Cinat, G., Dummer, R., Eggermont, A. M. M., Espinosa, E., Hauschild, A., Quirt, I., Robert, C., Schadendorf, D.
Publicado 2009

Ipilimumab retreatment in patients with pretreated advanced melanoma: the expanded access programme in Italy

por Chiarion-Sileni, V, Pigozzo, J, Ascierto, P A, Simeone, E, Maio, M, Calabrò, L, Marchetti, P, De Galitiis, F, Testori, A, Ferrucci, P F, Queirolo, P, Spagnolo, F, Quaglino, P, Carnevale Schianca, F, Mandalà, M, Di Guardo, L, Del Vecchio, M
Publicado 2014

Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study

por Long, G. V., Flaherty, K. T., Stroyakovskiy, D., Gogas, H., Levchenko, E., de Braud, F., Larkin, J., Garbe, C., Jouary, T., Hauschild, A., Chiarion-Sileni, V., Lebbe, C., Mandalà, M., Millward, M., Arance, A., Bondarenko, I., Haanen, J. B. A. G., Hansson, J., Utikal, J., Ferraresi, V., Mohr, P., Probachai, V., Schadendorf, D., Nathan, P., Robert, C., Ribas, A., Davies, M. A., Lane, S. R., Legos, J. J., Mookerjee, B., Grob, J.-J.
Publicado 2017

Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study

por Long, G V, Flaherty, K T, Stroyakovskiy, D, Gogas, H, Levchenko, E, de Braud, F, Larkin, J, Garbe, C, Jouary, T, Hauschild, A, Chiarion-Sileni, V, Lebbe, C, Mandalá, M, Millward, M, Arance, A, Bondarenko, I, Haanen, J B A G, Hansson, J, Utikal, J, Ferraresi, V, Mohr, P, Probachai, V, Schadendorf, D, Nathan, P, Robert, C, Ribas, A, Davies, M A, Lane, S R, Legos, J J, Mookerjee, B, Grob, J -J
Publicado 2019